Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.61 USD
-0.01 (-2.34%)
Updated Aug 16, 2024 02:12 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Kezar Life Sciences, Inc. (KZR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.33 | $13.00 | $2.00 | 1,082.26% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Kezar Life Sciences, Inc. comes to $7.33. The forecasts range from a low of $2.00 to a high of $13.00. The average price target represents an increase of 1% from the last closing price of $0.62.
Analyst Price Targets (3 )
Broker Rating
Kezar Life Sciences, Inc. currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 60%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/KZR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | William Blair | Matt Phipps | Hold | Hold |
7/22/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
11/14/2023 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 5 |
Average Target Price | $7.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 74 of 253 |
Current Quarter EPS Est: | -0.30 |